1.
Mediterr J Hematol Infect Dis
; 12(1): e2020054, 2020.
Article
in English
| MEDLINE | ID: covidwho-646687
2.
J Med Virol
; 2020.
Article
| WHO COVID | ID: covidwho-267001
ABSTRACT
Over the last months, pandemic SARS-CoV-2 caused a significant challenge for clinicians. Unfortunately, no approved and validated treatments are available. Intravenous tocilizumab, an antirheumatic drug, seems to be promising in counteracting cytokine storm caused by SARS-CoV-2 infection with associated clinical improvements. We report herein a case series of patients with COVID-19 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes. This article is protected by copyright. All rights reserved.